[{"id":"15959a9a-70ff-446f-ba15-1dcc1140abaf","acronym":"NRG-GY028","url":"https://clinicaltrials.gov/study/NCT05538897","created_at":"2022-09-14T18:56:09.184Z","updated_at":"2025-02-25T13:49:32.512Z","phase":"Phase 1/2","brief_title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","source_id_and_acronym":"NCT05538897 - NRG-GY028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1S1","pipe":"","alterations":" ","tags":["AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ipatasertib (RG7440) • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-20"},{"id":"36e9c4c3-28f9-471f-91db-41aa4b6178a4","acronym":"RAINBO","url":"https://clinicaltrials.gov/study/NCT05255653","created_at":"2022-02-24T13:52:52.644Z","updated_at":"2025-02-25T15:00:17.741Z","phase":"Phase 2/3","brief_title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","source_id_and_acronym":"NCT05255653 - RAINBO","lead_sponsor":"Leiden University Medical Center","biomarkers":" ER • POLE","pipe":" | ","alterations":" ER positive • MSI-H/dMMR • POLE mutation","tags":["ER • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 1615","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-11-28"},{"id":"d6f98f26-2498-46cc-812f-de883aab657a","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT03306472","created_at":"2021-01-18T16:19:53.588Z","updated_at":"2024-07-02T16:35:21.649Z","phase":"Phase 2","brief_title":"A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","source_id_and_acronym":"NCT03306472 - PIONEER","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1 • CDH2","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1 • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • megestrol"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 07/20/2017","start_date":" 07/20/2017","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-01-30"},{"id":"4415345d-a697-4291-8d70-7d0798eb8ec4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05945407","created_at":"2023-07-14T18:08:53.504Z","updated_at":"2024-07-02T16:35:42.902Z","phase":"","brief_title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","source_id_and_acronym":"NCT05945407","lead_sponsor":"Peking University People's Hospital","biomarkers":" TP53 • PTEN • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • PTEN • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-07-14"},{"id":"3490ad62-c32a-4563-a2d8-c13c52389445","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316467","created_at":"2022-04-07T12:57:05.641Z","updated_at":"2024-07-02T16:35:46.763Z","phase":"Phase 2/3","brief_title":"Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma","source_id_and_acronym":"NCT05316467","lead_sponsor":"Xiaojun Chen","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2023-05-31"},{"id":"cd62df59-cbe8-4f1b-b0fe-9ae110164539","acronym":"MEGA","url":"https://clinicaltrials.gov/study/NCT03024580","created_at":"2021-01-18T14:53:10.909Z","updated_at":"2024-07-02T16:36:56.887Z","phase":"Phase 2","brief_title":"A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer","source_id_and_acronym":"NCT03024580 - MEGA","lead_sponsor":"Instituto Nacional de Cancer, Brazil","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2019-08-15"},{"id":"17cca8cf-da21-42ab-ada5-67fd34554e5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00910091","created_at":"2021-01-18T03:30:58.793Z","updated_at":"2024-07-02T16:37:03.352Z","phase":"Phase 2","brief_title":"The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00910091","lead_sponsor":"Ipsen","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e megestrol • irosustat (BN 83495)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 01/01/2012","primary_completion_date":" 01/01/2012","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2019-01-30"},{"id":"39d94fa9-761b-4f7d-9a9b-52a865613e4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777930","created_at":"2021-01-18T18:41:15.246Z","updated_at":"2024-07-02T16:37:04.517Z","phase":"Phase 4","brief_title":"The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol","source_id_and_acronym":"NCT03777930","lead_sponsor":"Shenzhen Fifth People's Hospital","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e thalidomide • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 06/10/2021","study_completion_date":" 06/10/2021","last_update_posted":"2018-12-19"},{"id":"6b85bef4-ae95-4a3b-bab3-ab9da338b349","acronym":"","url":"https://clinicaltrials.gov/study/NCT02990728","created_at":"2021-01-18T14:42:39.840Z","updated_at":"2024-07-02T16:37:27.129Z","phase":"Phase 2","brief_title":"Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer","source_id_and_acronym":"NCT02990728","lead_sponsor":"Chang Gung Memorial Hospital","biomarkers":" ER • PGR • MUC16","pipe":"","alterations":" ","tags":["ER • PGR • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 120","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2016-12-13"}]